Start Over

The case of methotrexate and the lung: Dr Jekyll and Mr Hyde.

Authors :: Cottin V
Bendstrup E
Bonniaud P
Nasser M
Spagnolo P
Valenzuela C
Kolb M
Source :: The European respiratory journal [Eur Respir J] 2021 Feb 11; Vol. 57 (2). Date of Electronic Publication: 2021 Feb 11 (Print Publication: 2021).
Publication Year :: 2021
Abstract: Competing Interests: Conflict of interest: V. Cottin has received fees for consultancy from Actelion, Boehringer Ingelheim, Bayer, Biogen Idec, GSK, MSD, Novartis, Roche, Sanofi and Galapagos; has received lecture fees from Actelion, Boehringer Ingelheim, Novartis, Roche and Sanofi; has received reimbursement for travel to medical meetings from Actelion, Boehringer Ingelheim and Roche; has received fees for development of educational presentations from Boehringer Ingelheim; has acted as a member of an adjudication committee for Gilead; has received grants to his institution from Boehringer Ingelheim and Roche; and has acted as a member of data and safety monitoring boards for Promedior, Celgene and Galecto. Conflict of interest: E. Bendstrup has nothing to disclose. Conflict of interest: P. Bonniaud has nothing to disclose. Conflict of interest: M. Nasser has nothing to disclose. Conflict of interest: P. Spagnolo has nothing to disclose. Conflict of interest: C. Valenzuela has nothing to disclose. Conflict of interest: M. Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic (now Liminal Biosciences) and Pieris; grants from Avalyn; and personal fees from AstraZeneca, Novartis, Cipla, Bluefin Biomedicine, Algernon and Medscape